GlassScriptPhysician profile
Gottfried Konecny
NPI 1427190115
$402,078.27
in general payments reported to CMS, 2019-2025
21 companies · $70K in 2025
The $70K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $50K · 2021: $36K · 2022: $33K · 2023: $42K · 2024: $75K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Consulting Fee: $36K · Travel and Lodging: $13K · Food and Beverage: $3,366 · Education: $98.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,419.50 |
| Consulting Fee | $36,093.50 |
| Travel and Lodging | $12,642.33 |
| Food and Beverage | $3,366.30 |
| Education | $98.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $97,690.61 | 2019-2025 | Lynparza |
| Abbvie INC. | $96,320.08 | 2024-2025 | |
| Glaxosmithkline, LLC. | $62,175.12 | 2020-2024 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $51,493.62 | 2019-2024 | Lynparza, Keytruda |
| Tesaro, INC. | $27,169.42 | 2019 | |
| Clovis Oncology, INC. | $26,772.66 | 2019-2020 | |
| Immunogen, INC. | $20,177.14 | 2023-2024 | Elahere, Elahere |
| Foundation Medicine, INC. | $11,625.00 | 2020 | |
| Genmab U.S., INC. | $3,301.08 | 2024 | Epkinly |
| Gilead Sciences, INC. | $2,858.61 | 2025 | |
| Myriad Genetic Laboratories, INC. | $2,372.92 | 2020 | |
| Daiichi Sankyo INC. | $70.23 | 2025 | Enhertu, Datroway |
| Genzyme Corporation | $24.97 | 2022 | |
| Stemline Therapeutics INC. | $18.11 | 2025 | Orserdu |
| Array Biopharma INC | $8.70 | 2024 | Braftovi, Mektovi, Tukysa |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gottfried Konecny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.